iShares US Medical Devices

Arrowstreet Capital Significantly Increases Stake in Intuitive Surgical

Intuitive Surgical Completes Acquisition of Da Vinci and Ion Systems' Distribution Business in Southern Europe

Abbott Announces FreeDM2 Trial Results, Stock Price Drops

Bank of Montreal Reduced Stake in Becton Dickinson

Edward Lifesciences Vice President Sells Common Stock

Intuitive Surgical's EVP and CMO Sells Company Shares

Stryker Employees Find Remote Devices Cleared

Citigroup Raises Intuitive Surgical Stock Rating to Buy

MiniMed Group, Inc. Obtains Abbott CE Certification

Medtronic to Acquire Scientia Vascular

Russell Investments Reduced Holdings in IDEXX Laboratories in Q3

ResMed Receives 'Moderate Buy' Consensus Recommendation from Fourteen Brokers

Abbott Completes $20 Billion in Senior Notes Offering

Stryker Launches Smart Hospital Platform

GE HealthCare's Diagnostic Viewer Receives FDA Approval

Russell Investments Increased Holdings in Edwards Lifesciences in Q3

Analyst Josh Jennings Gives Boston Scientific a Buy Rating

Orion Portfolio Solutions LLC increased its holdings in Boston Scientific

IFG Advisory LLC reduced holdings in Medtronic

Boston Scientific Receives NMPA Approval for New Cardiac Electrophysiology 3D Mapping System

bioAffinity Tech

Firefly Neuroscience

Silvaco

eLong Power

T-REX 2X Long UPXI Daily Target ETF

Polaryx Therapeutics

TCW Strategic Income Fund, Inc.

Stak

iSpecimen

Oruka Therapeutics

Pinned News

置顶新闻

Stryker Corporation $SYK Position Trimmed by Comerica Bank

Comerica Bank reduced its holdings in Stryker Corporation (NYSE:SYK) by 2.6% in Q3, owning 122,337 shares valued at $45.2 million. Several institutional investors also modified their positions. Analysts have set a consensus target price of $428.61 for Stryker, with a "Moderate Buy" rating. The stock opened at $336.95, with a market cap of $128.95 billion. Stryker recently announced a quarterly dividend of $0.88 per share, with a yield of 1.0%. Insider Ronda E. Stryker sold 250,000 shares, reducing her stake by 9.23%.

Market Beat

Stryker

SPDR S&P Health Equip

Banque Transatlantique SA reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 32.6% in Q3, now holding 37,434 shares valued at $2.91 million. Other institutional investors also adjusted their positions, with Fjarde AP Fonden increasing its stake by 7% and Atlantic Union Bankshares raising its position by 2,240.9%. Edwards Lifesciences shares fell 3.3% recently, with a market cap of $47.52 billion and a P/E ratio of 44.71. The company reported a revenue increase of 13.3% year-over-year, but missed EPS estimates in its last quarterly earnings.

Edwards Lifesciences

Banque Transatlantique SA Has $2.91 Million Position in Edwards Lifesciences Corporation $EW

MASS

Wall Street Zen upgraded 908 Devices (NASDAQ:MASS) from a "hold" to a "buy" rating. The company has an average rating of "hold" with a consensus price target of $12.00. 908 Devices reported a quarterly EPS of ($0.05), beating estimates, with revenue of $17.38 million. CFO Joseph H. Iv Griffith sold 23,175 shares recently. Institutional investors hold 88.06% of the stock. 908 Devices specializes in portable analytical instruments for chemical detection.

908 Devices

908 Devices (NASDAQ:MASS) Rating Increased to Buy at Wall Street Zen

HNGE

Hinge Health's stock recently closed at $45.00, reflecting a 16.1% gain over 30 days but a decline of 2.5% in the last week. A Discounted Cash Flow analysis suggests the stock is undervalued by 71%, with an intrinsic value of $155.02 per share. However, its Price-to-Sales ratio of 6.03x is above industry averages, indicating it may be overvalued. Analysts provide varying fair value estimates, ranging from $43.40 to $72.00, prompting investors to reassess its market position and potential risks.

Simplywall

Hinge Health

SPDR S&P Health

iShares US Healthcare Providers

Is It Time To Reassess Hinge Health (HNGE) After Its Recent Share Price Rebound?

LABU

SBIO

Tandem Diabetes Care has launched its FDA-cleared Tandem Mobi mobile app for U.S. Android users, allowing control of its automated insulin delivery system from select smartphones. This expansion is expected to enhance user integration and strengthen Tandem's diabetes management ecosystem. The company projects 2026 sales of approximately $1.065 billion to $1.085 billion, despite recent losses. Analysts have varying revenue growth estimates, with some predicting a more pessimistic outlook. The Android launch may influence Tandem's long-term investment narrative and revenue targets.

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Tandem Diabetes

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

The Bull Case For Tandem Diabetes Care (TNDM) Could Change Following Android Launch Of Tandem Mobi App

RPID

Rapid Micro Biosystems Faces ESG-Related Reputational and Operational Risks Amid Evolving Sustainability Rules

Tip Ranks

Rapid Micro Biosystems

Rapid Micro Biosystems Faces ESG-Related Reputational and Operational Risks Amid Evolving Sustainability Rules

Noveris Health Sciences Boosts Investor Outreach With New Website and Fairfax Partners Mandate

iShares Global Healthcare

VG Health

Ark Genomic Revolution ETF

iShares US Pharma

Black-Hlth Sci T

Health Care Select Sector SPDR

Minerva Neurosciences

USANA Health Sciences

NeuroMetrix

Noveris Health Sciences Boosts Investor Outreach With New Website and Fairfax Partners Mandate

516820

159883

Ocumetics Grants Stock Options to IR Advisor as It Advances Novel Intraocular Lens

Ping An CSI Medicine and Medical Device Innovation ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Minsheng Royal CSI Biotechnology Theme ETF

iShares Genomics Immunology and Healthcare ETF

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Proshares UltraShort Nasdaq Biotech

Hwabao WP CSI Medical Service ETF

ChinaAMC CSI All Share Health Care Devices ETF

Ocumetics Grants Stock Options to IR Advisor as It Advances Novel Intraocular Lens

MOVE

Medacta Group (SWX:MOVE) reported strong 2025 results with €684 million in revenue, a 29% EBITDA margin, and a 31% increase in net profit. A proposed dividend of CHF 1.10 per share is nearly 60% higher. The share price is CHF155.8, reflecting a 5.7% return over one month and a 24.5% return over one year. Analysts suggest the stock is undervalued at a fair value of CHF177.36, despite a high P/E ratio of 36.2x. Caution is advised due to potential slower market growth and price erosion affecting margins.

Movano

Assessing Medacta Group (SWX:MOVE) Valuation After Strong Earnings And Higher Dividend Proposal

STAA

STAAR Surgical Company (NASDAQ:STAA) Director Broadwood Partners, L.P. acquired 299,432 shares at an average price of $18.12, totaling $5,425,707.84. This purchase increased their ownership by 1.93%, bringing their total shares to 15,807,825, valued at approximately $286.4 million. The acquisition was disclosed in an SEC filing. Additionally, Broadwood Partners made several other purchases recently, including 316,017 shares at $18.61 and 54,764 shares at $17.52. STAAR Surgical's stock performance shows a recent trading price of $18.84, with a market cap of $932.77 million.

STAAR Surgical

STAAR Surgical (NASDAQ:STAA) Director Acquires $5,425,707.84 in Stock

SKIN

Beauty Health Earnings Call Balances Margins And Growth

Beauty Health

Beauty Health Earnings Call Balances Margins And Growth

LABD

Ocumetics Technology Corp. has issued 500,000 incentive stock options to Howard Group Inc. as part of their agreement. Each option allows Howard Group to purchase one common share at $0.42 for two years, vesting quarterly over twelve months. The shares from these options will have a four-month resale restriction. Ocumetics is focused on developing advanced vision correction solutions, including a new intraocular lens designed to eliminate the need for corrective lenses. This announcement includes forward-looking statements regarding the company's research and development plans.

The newswire.ca

Direxion S&P Biotech Bear 3X

Oncocyte

Ocumetics Announces Issuance of Stock Options

BMBL

BZFD

FedEx has surpassed UPS in market capitalization, reflecting Wall Street's approval of its cost-cutting measures. Meanwhile, Stryker faces operational challenges due to a cyberattack, and Amazon partners with Cerebras for advanced computing. TotalEnergies halts production in the Middle East amid regional conflicts, while Elon Musk announces a rebuild of xAI. BuzzFeed's decline is attributed to management failures, and Bumble's stock sees a significant rise as it introduces AI features. Other notable news includes Apple reducing App Store fees in China and Starbucks union negotiations for higher wages.

- FedEx has overtaken UPS in market capitalization due to cost-cutting measures, although UPS still delivers more packages.  
- TotalEnergies has halted production in Qatar and Iraq amid regional conflicts, affecting about 15% of its output.  
- Amazon is partnering with Cerebras to enhance its inference computing capabilities through a new chip deal.

MorningStar

Bumble

FedEx

BuzzFeed

Amazon

Starbucks

T-Rex 2X Long Apple Daily Target ETF

Direxion Daily AMZN Bull 2X Shares

Amplify Online Retail ETF

Roundhill AMZN WeeklyPay ETF

ProShares Online Retail

Global X E-commerce ETF

Pacer Industrials and Logistics ETF

iShares US Transportation ETF

SPDR S&P Retail ETF

SPDR S&P Transp

Direxion Daily AAPL Bull 2X Shares

GraniteShares 2x Long AMZN Daily ETF

Proshares Supply Chain Logistics ETF

GraniteShares 2x Long AAPL Daily ETF

VanEck Retail ETF

Dow Jones Top Company Headlines at 7 PM ET: FedEx Overtakes UPS as the New King of Delivery | Cyberwarfare ...

LFWD

LFCR

Lifecare Insider-Linked Investor Cuts Stake but Retains Major Holding

Lifeward

Lifecore Biomedical

Lifecare Insider-Linked Investor Cuts Stake but Retains Major Holding

Eli Lilly has established itself as a leader in the weight loss market with its drug Zepbound, but competition is increasing as other companies like Regeneron, Roche, and Novo Nordisk are developing promising candidates. Despite this, none are expected to challenge Zepbound in the near term. Eli Lilly is also advancing its own candidates, including orforglipron and retatrutide, which could further solidify its market position. The company reported a 45% revenue increase in 2025, indicating strong financial health and continued investment in technology and drug discovery.

nasdaq

Eli Lilly

Direxion Daily LLY Bull 2X Shares

Roche

ROCHE HOLDINGS AG

Defiance Daily Target 2X Long LLY ETF

Regeneron Pharma

Novo Nordisk AS

Invesco Nasdaq Biotechnology ETF

Is Eli Lilly's Weight Loss Empire in Trouble?

PODD

Securities fraud investigation into Insulet Corporation (PODD) has been announced by Glancy Prongay Wolke & Rotter LLP. The investigation concerns potential violations of federal securities laws following a disclosure on March 12, 2026, regarding a voluntary Medical Device Correction for Omnipod® 5 Pods, which led to a 6.9% drop in stock price. Shareholders who lost money are urged to contact the law firm for potential claims.

Insulet

Securities Fraud Investigation Into Insulet Corporation (PODD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

iShares US Medical Devices(IHI.US)

Stryker Corporation $SYK Position Trimmed by Comerica Bank

Banque Transatlantique SA Has $2.91 Million Position in Edwards Lifesciences Corporation $EW

908 Devices (NASDAQ:MASS) Rating Increased to Buy at Wall Street Zen

Is It Time To Reassess Hinge Health (HNGE) After Its Recent Share Price Rebound?

The Bull Case For Tandem Diabetes Care (TNDM) Could Change Following Android Launch Of Tandem Mobi App